Subtype
Malignant Uterine Neoplasm
CI-CAN-00005955Explore in graph →
824 active trials7 approved drugs44 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005955Explore in graph →
Clinical trials
3,291 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (333)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01168232 | Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT01220609 | Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT01247571 | Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT01266447 | Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT00006089 | Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2019 | clinicaltrials |
| NCT00025233 | Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00025506 | Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00075400 | Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00095979 | Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00096447 | Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00301964 | Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00025220 | Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00378911 | Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00416455 | Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer | completed | Phase 1 / Phase 2 | 384 | National Cancer Institute (NCI)NIH | 4 | Jul 23, 2019 | clinicaltrials |
| NCT00462826 | VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00723255 | Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00729586 | Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer | completed | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00993616 | Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin | completed | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01011933 | Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01637961 | Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01523678 | Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers | completed | Phase 2 | 108 | Belgian Gynaecological Oncology GroupOTHER | 1 | Jul 10, 2019 | clinicaltrials |
| NCT01094132 | Combined Digital Colposcopy Analysis to Improve Cervical Precancer and Cancer Detection(MDC_Algo) | completed | Phase 2 | 551 | British Columbia Cancer AgencyOTHER | 2 | Jul 5, 2019 | clinicaltrials |
| NCT02323646 | Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids | completed | Phase 2 | 42 | Repros Therapeutics Inc.INDUSTRY | 1 | Jun 25, 2019 | clinicaltrials |
| NCT00958334 | Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003 | completed | Phase 2 | 65 | Repros Therapeutics Inc.INDUSTRY | 1 | Jun 18, 2019 | clinicaltrials |
| NCT02467907 | Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer | completed | Phase 2 | 152 | Hoffmann-La RocheINDUSTRY | 18 | Jun 3, 2019 | clinicaltrials |
| NCT01289041 | BKM120 as Second-line Therapy for Advanced Endometrial Cancer | completed | Phase 2 | 70 | Novartis PharmaceuticalsINDUSTRY | 13 | May 30, 2019 | clinicaltrials |
| NCT01230996 | Dose Escalation Study of Simultaneous Boost Intensity-Modulated Radiotherapy for Locally Advanced Cervical Cancer(DEPICT) | completed | Phase 1 / Phase 2 | 22 | Barts & The London NHS TrustOTHER | 1 | Apr 24, 2019 | clinicaltrials |
| NCT01267253 | Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 31 | Gynecologic Oncology GroupNETWORK | 1 | Mar 20, 2019 | clinicaltrials |
| NCT02128126 | Study of the Therapeutic Vaccine (ISA101/ISA101b) to Treat Advanced or Recurrent Cervical Cancer(CervISA) | completed | Phase 1 / Phase 2 | 93 | ISA PharmaceuticalsINDUSTRY | 3 | Mar 6, 2019 | clinicaltrials |
| NCT00331760 | Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery | completed | Phase 2 | 106 | Radiation Therapy Oncology GroupNETWORK | 2 | Feb 26, 2019 | clinicaltrials |
| NCT00910091 | The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer | completed | Phase 2 | 73 | IpsenINDUSTRY | 12 | Jan 30, 2019 | clinicaltrials |
| NCT01010126 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | completed | Phase 2 | 252 | National Cancer Institute (NCI)NIH | 2 | Jan 25, 2019 | clinicaltrials |
| NCT00231842 | Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus | completed | Phase 2 | 30 | Montefiore Medical CenterOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT00939809 | A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 31 | Gynecologic Oncology GroupNETWORK | 1 | Jan 15, 2019 | clinicaltrials |
| NCT00087126 | Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 27 | Gynecologic Oncology GroupNETWORK | 1 | Jan 8, 2019 | clinicaltrials |
| NCT00114218 | Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer | completed | Phase 2 | 28 | Gynecologic Oncology GroupNETWORK | 1 | Jan 8, 2019 | clinicaltrials |
| NCT00309959 | ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 37 | Gynecologic Oncology GroupNETWORK | 1 | Jan 8, 2019 | clinicaltrials |
| NCT00006079 | Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia | completed | Phase 2 | 150 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 25, 2018 | clinicaltrials |
| NCT02091050 | 2D vs 3D Planning for High-Dose Rate (HDR) Gynecological Brachytherapy | completed | Phase 2 | 60 | AC Camargo Cancer CenterOTHER | 1 | Aug 31, 2018 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT00121173 | Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia | completed | Phase 1 / Phase 2 | 16 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 20, 2018 | clinicaltrials |
| NCT01553539 | Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery | completed | Phase 2 | 20 | Wake Forest University Health SciencesOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT00659360 | AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 2 | Jun 29, 2018 | clinicaltrials |
| NCT01764802 | Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer | completed | Phase 2 | 100 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT00075569 | SGN-00101 Immunotherapy in Treating Patients With Grade III Cervical Intraepithelial Neoplasia | completed | Phase 2 | 64 | Albert Einstein College of MedicineOTHER | 1 | May 21, 2018 | clinicaltrials |
| NCT00483327 | Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate | completed | Phase 2 | 31 | NYU Langone HealthOTHER | 1 | Apr 4, 2018 | clinicaltrials |
| NCT00369122 | Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 2 | Mar 20, 2018 | clinicaltrials |
| NCT01005329 | Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 3 | Mar 15, 2018 | clinicaltrials |
| NCT01642082 | Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 28 | Gynecologic Oncology GroupNETWORK | 1 | Mar 13, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Aug 8, 2019source: clinicaltrials